Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when AIDX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alerts20/20 Biolabs slashes warrant exercise price 80% to $2.25, enabling major dilution
Filed April 28, 2026 · Period ending April 23, 2026 · ~1 min read
Key Changes
-
high
Company cut warrant exercise price from $8.00-$11.42 to $2.25 per share for investor Streeterville, covering 3.6M shares—an 80% discount from February's $11.42 direct listing price, signaling significant stock decline.
Item 1.01 verify on EDGAR → -
high
Repricing makes it dramatically cheaper for Streeterville to convert warrants into common stock, potentially diluting existing shareholders by millions of shares at a fraction of the recent listing price.
Item 1.01 verify on EDGAR → -
medium
Company retains 90-day right to cancel the repricing with two days' notice, though Streeterville can still exercise warrants at $2.25 during that notice period, limiting the company's ability to prevent dilution.
Item 1.01 verify on EDGAR → -
medium
Streeterville has provided $5.5M in financing through convertible notes and preferred stock since November 2025, making them a significant creditor whose warrant exercise could substantially increase their equity stake.
Item 1.01 verify on EDGAR →
Summary
20/20 Biolabs dramatically repriced warrants held by investor Streeterville Capital, slashing the exercise price from $8.00-$11.42 down to just $2.25 per share. The warrants cover up to 3.6 million shares, and the 80% discount from the company's February 2026 direct listing price of $11.42 suggests the stock has fallen sharply in just two months.
This repricing makes it far cheaper for Streeterville to convert warrants into common stock, which would significantly dilute existing shareholders. Streeterville has been a key financier, providing $5.5 million through convertible notes and preferred stock since November 2025. The warrant repricing appears designed to keep this critical investor engaged, but comes at a steep cost to current shareholders.
The company does retain a 90-day option to cancel the repricing, though Streeterville can still exercise during any notice period. Investors should monitor whether Streeterville exercises these warrants in coming weeks and watch for any disclosure of the company's current stock price or trading volume, which would confirm whether shares have indeed collapsed from the $11.42 listing price. Any further financing announcements or additional warrant modifications would signal continued financial pressure.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company has the right to terminate the Amendment within ninety (90) days of execution of the Amendment upon at least two (2) trading days’ written notice, during which time Streeterville may exercise the Warrants at the foregoing price.
The company retains a 90-day window to cancel the warrant repricing amendment with two trading days' notice. However, during that notice period, Streeterville can still exercise the warrants at the reduced $2.25 price. This gives the company some flexibility to reverse the repricing if market conditions improve, though the investor maintains exercise rights during the notice period.
Added in current filing · verify on EDGAR → · paraphrased
As previously disclosed, on November 17, 2025, the Company entered into a securities purchase agreement with Streeterville Capital, LLC ("Streeterville"), pursuant to which the Company agreed to offer and sell to Streeterville, in a private placement transaction, secured convertible promissory notes in the aggregate principal amount of up to $570,000 and warrants to purchase a number of shares of common stock equal to $1,000,000 divided by the lower of (i) $8.00 and (ii) the Valuation based Bid Price or Compelling Evidence-based Bid Price, as submitted by the Company and accepted by The Nasdaq Stock Market ("Nasdaq") in connection with the Company's direct listing application with Nasdaq and calculated in accordance with Nasdaq Listing Rule IM-5505-1 (the "Nasdaq Price"). On February 19, 2026, the Company's direct listing was completed with a Nasdaq Price of $11.42.
The filing provides context that the company completed a Nasdaq direct listing on February 19, 2026 at $11.42 per share, and has raised $5.5 million from Streeterville through convertible notes and preferred stock since November 2025. The warrant repricing to $2.25 represents an 80% discount from the direct listing price, suggesting the stock price has declined significantly since the February listing.
Event · Item 9.01 — Financial Statements and Exhibits
20/20 Biolabs executed a Global Amendment with warrant holder Streeterville Capital on April 23, 2026, modifying terms of three prior warrants.
Added in current filing · verify on EDGAR →
Global Amendment, dated April 23, 2026, between Streeterville Capital, LLC and 20/20 Biolabs, Inc.
The company entered into a Global Amendment with Streeterville Capital, LLC on April 23, 2026. This amendment appears to modify the terms of three previously issued warrants to purchase common stock dated November 17, 2025, February 9, 2026, and February 19, 2026. The specific terms of the amendment are not disclosed in this 8-K filing, as the full exhibit is referenced but not included in the body text.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify